(Q36546507)

14 August 2017

1 reference

title

Re-assessing the relationship between cholesterol, statins and Alzheimer's disease (English)

1 reference

14 August 2017

0 references

R Bryant

3

0 references

author name string

B Wolozin

1

1 reference

14 August 2017

J Manger

2

1 reference

14 August 2017

J Cordy

4

1 reference

14 August 2017

R C Green

5

1 reference

14 August 2017

A McKee

6

1 reference

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

Acta neurologica Scandinavica. Supplementum

14 August 2017

published in

1 reference

14 August 2017

volume

185

1 reference

14 August 2017

page(s)

63-70

1 reference

Apolipoprotein E polymorphism and Alzheimer's disease.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

LRP: a multifunctional scavenger and signaling receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Loss of apolipoprotein E receptor LR11 in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Apolipoprotein E receptors: linking brain development and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Potential genetic markers of sporadic Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

The H+ allele of the lipoprotein lipase (LPL) HindIII intronic polymorphism and the risk for sporadic late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

The association between APOE and dementia does not seem to be mediated by vascular factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Apolipoprotein E polymorphism in Pick's disease and in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Neuronal membrane cholesterol loss enhances amyloid peptide generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Serum lipoprotein levels, statin use, and cognitive function in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Genetic association of CYP46 and risk for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

No association between polymorphisms in the lectin-like oxidised low density lipoprotein receptor (ORL1) gene on chromosome 12 and Alzheimer's disease in a UK cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Genetic association of low density lipoprotein receptor and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Lipoprotein lipase mutations and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Cardiovascular risk factors and Alzheimer's disease: a genetic association study in a population aged 85 or over.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

No association between the lipoprotein lipase S447X polymorphism and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Lack of association of two lipoprotein lipase polymorphisms with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00687.X

10.1111/J.1600-0404.2006.00687.X

21 January 2018

Identifiers

DOI

0 references

1 reference